Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.29 Average Price Target from Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $22.29.

Several equities analysts recently commented on the company. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Canaccord Genuity Group raised their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, Guggenheim raised their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, March 13th.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock traded down $0.04 during mid-day trading on Friday, reaching $9.00. The stock had a trading volume of 357,463 shares, compared to its average volume of 671,625. The firm's 50 day simple moving average is $8.24 and its 200 day simple moving average is $8.05. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76. The firm has a market cap of $492.12 million, a PE ratio of -4.74 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The company had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same quarter last year, the company earned ($0.40) EPS. On average, analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock valued at $172,000 after buying an additional 6,966 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at $53,000. Millennium Management LLC increased its stake in shares of Zevra Therapeutics by 138.2% in the 4th quarter. Millennium Management LLC now owns 233,132 shares of the company's stock valued at $1,944,000 after buying an additional 135,246 shares during the period. Deutsche Bank AG increased its stake in shares of Zevra Therapeutics by 25.4% in the 4th quarter. Deutsche Bank AG now owns 50,906 shares of the company's stock valued at $425,000 after buying an additional 10,306 shares during the period. Finally, ProShare Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at $145,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.